# Eli Lilly & Company (NYSE: LLY), Indianapolis, IN – FDA Inspections

Source: https://www.keypedia.com/companies/eli-lilly-company/fc56eed7-d261-4de3-865e-c2aa54162adf

> Inspection records and compliance data for Eli Lilly & Company in Indianapolis, Indiana. 36 FDA inspections on record, 5 Form 483s, last inspected January 09, 2026. Publicly traded as NYSE: LLY.

---

## Details

- Name: Eli Lilly & Company
- FEI Number: 1819470
- Facility Type: Sterile Human Drug Manufacturer
- Address Line 1: 1 Lilly Corporate Ctr
- City: Indianapolis
- State: Indiana
- Zip Code: 46285
- Country Name: United States
- Address: 1 Lilly Corporate Ctr, Indianapolis, Indiana 46285, United States
- Country: United States

## Stock

- Stock ticker: LLY
- Exchange: NYSE
- Share price: $1,430.13
- Market cap: $1.3T
- Price as of: November 13, 2026

## Related Documents

- FDA Inspection 1298628 - Eli Lilly & Company - 2026-01-09 — source: FDA, date: January 9, 2026
- FDA Inspection 1298628 - Eli Lilly & Company - 2026-01-09 — classification: No Action Indicated (NAI), source: FDA, date: January 9, 2026
- [483 - Eli Lilly & Company - 2025-05-20](https://www.keypedia.com/records/483/eli-lilly-company/885fecd9-f6cd-48fd-90eb-66d12ec35d07) — source: FDA, date: May 20, 2025
- FDA Inspection 1270621 - Eli Lilly & Company - 2025-05-20 — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 20, 2025
- [FDA Inspection 1270621 - Eli Lilly & Company - 2025-05-20](https://www.keypedia.com/records/fda_inspections/eli-lilly-company/809cae3e-94ad-47cf-a116-8f4799dc570f) — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 20, 2025
- FDA Inspection 1260339 - Eli Lilly & Company - 2025-03-27 — source: FDA, date: March 27, 2025
- FDA Inspection 1260339 - Eli Lilly & Company - 2025-03-27 — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 27, 2025
- FDA Inspection 1229895 - Eli Lilly & Company - 2025-01-15 — source: FDA, date: January 15, 2025
- FDA Inspection 1229895 - Eli Lilly & Company - 2025-01-15 — classification: No Action Indicated (NAI), source: FDA, date: January 15, 2025
- [483 - Eli Lilly & Company - 2023-10-06](https://www.keypedia.com/records/483/eli-lilly-company/f0349542-8a47-4147-9164-7ecacf1fcd4e) — source: FDA, date: October 6, 2023
- [FDA Inspection 1220489 - Eli Lilly & Company - 2023-10-06](https://www.keypedia.com/records/fda_inspections/eli-lilly-company/4c2819f7-b6f3-4b07-998f-0338105e6e0b) — source: FDA, date: October 6, 2023
- [483 - Eli Lilly & Company - 2023-09-15](https://www.keypedia.com/records/483/eli-lilly-company/49ac02bf-312b-43ae-96e2-4cf015602e85) — source: FDA, date: September 15, 2023
- [FDA Inspection 1217806 - Eli Lilly & Company - 2023-09-15](https://www.keypedia.com/records/fda_inspections/eli-lilly-company/e798a151-3f7b-4506-b880-321ebcca71a6) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 15, 2023
- [483 - Eli Lilly & Company - 2023-06-16](https://www.keypedia.com/records/483/eli-lilly-company/ad3d5c22-c165-4f63-91cc-163c31217be2) — source: FDA, date: June 16, 2023
- [EIR - Eli Lilly & Company - 2023-05-18](https://www.keypedia.com/records/eir/eli-lilly-company/15f9ed35-a475-4557-b1f2-753ea60f17a2) — source: FDA, date: May 18, 2023
- [EIR - Eli Lilly & Company - 2022-10-21](https://www.keypedia.com/records/eir/eli-lilly-company/a6cfae52-180e-4b9d-9b15-509286f24bc5) — source: FDA, date: October 21, 2022
- [483 - Eli Lilly & Company - 2022-10-21](https://www.keypedia.com/records/483/eli-lilly-company/18ee6771-3641-4129-8c43-efe275d11ed4) — source: FDA, date: October 21, 2022
- [483 - Eli Lilly & Company - 2022-10-17](https://www.keypedia.com/records/483/eli-lilly-company/0122f6aa-1103-4f80-a3f6-6abe81842b50) — source: FDA, date: October 17, 2022
- [483 - Eli Lilly & Company - 2021-03-16](https://www.keypedia.com/records/483/eli-lilly-company/9fdf10fc-bc85-478c-affd-9279176c5cb7) — source: FDA, date: March 16, 2021
- [483_RESPONSE - Eli Lilly & Company - 2021-03-16](https://www.keypedia.com/records/483_response/eli-lilly-company/48bca0f9-fb52-4f51-9e65-4d0fd6283a21) — source: FDA, date: March 16, 2021

## Related Companies

- [Amgen, Inc.](https://www.keypedia.com/companies/amgen-inc/85ec512e-6991-42ee-9cd5-148cfe0ed3e8)
- [Biological E. Limited](https://www.keypedia.com/companies/biological-e-limited/a02640a2-3dc0-448e-9a4f-df7e189939e4)
- [Amgen Manufacturing Ltd](https://www.keypedia.com/companies/amgen-manufacturing-ltd/cecb788c-4cd6-4c26-9331-7b68b4f12369)
- [FUJIFILM Diosynth Biotechnologies Denmark ApS](https://www.keypedia.com/companies/fujifilm-diosynth-biotechnologies-denmark-aps/513b3c42-1517-43bc-936a-d3edd26bed70)
- [Patheon Pharmaceuticals Inc.](https://www.keypedia.com/companies/patheon-pharmaceuticals-inc/f1ef6b53-3c20-4c22-9ef3-fd05fdb9f35b)
- [Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany](https://www.keypedia.com/companies/halo-pharmaceutical-inc-dba-cambrex-whippany/1464443d-ae5a-4d06-959c-d1ccb1b213a2)
- [Boehringer Ingelheim Fremont, Inc.](https://www.keypedia.com/companies/boehringer-ingelheim-fremont-inc/3d7d0ca7-27cd-4223-8ade-7193417c9861)
- [Sumitomo Dainippon Pharma Co., Ltd.](https://www.keypedia.com/companies/sumitomo-dainippon-pharma-co-ltd/40ead027-5fd5-4deb-a37b-40301cffd612)
- [ALK-Abello, Inc.](https://www.keypedia.com/companies/alk-abello-inc/b626f86d-b379-45aa-96d2-0661e9d1c981)
- [Advanced Accelerator Applications (Italy) srl](https://www.keypedia.com/companies/advanced-accelerator-applications-italy-srl/09ac059c-6735-4082-8674-a88476dbdbc6)

## Related Officers

- [Investigator](https://www.keypedia.com/people/rafeeq-a-habeeb/ac58c0b7-bd42-4037-8ccb-bf0351b7744f)
- [Investigator](https://www.keypedia.com/people/muna-algharibeh/0f0dbd13-b36a-408d-8e42-4625f8de905d)
- [Qiao Y. Bobo](https://www.keypedia.com/people/qiao-y-bobo/c57c1128-9181-4c2a-81f9-cb9a171ece38)
- [Senior Regulatory Specialist](https://www.keypedia.com/people/wayne-e-seifert/e92e1f10-c61e-4b08-9156-25907e5e2942)
- [Director of Compliance](https://www.keypedia.com/people/nicholas-f-lyons/e52983af-3992-493c-addd-ff1dfa59eefb)
- [Program Division Director](https://www.keypedia.com/people/art-o-czabaniuk/37f1e249-9ee6-4275-9c28-391d93659b85)